AbbVie (ABBV) FCF Margin Growth (3y) (2015 - 2026)
Powered by 
Analysis
AbbVie (ABBV) FCF Margin Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 1,461.00 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | -2,596.00 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 874.00 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 982.00 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 1,832.00 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 1,733.00 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | -176.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 1,592.00 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | -2,476.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,596.00 |
| Mar 31, 2026 | -911.00 |
| Dec 31, 2025 | -1,830.00 |
| Sep 30, 2025 | -802.00 |
| Jun 30, 2025 | -167.00 |
| Mar 31, 2025 | -2,456.00 |
| Dec 31, 2024 | 1,191.00 |
| Sep 30, 2024 | -1,787.00 |
| Jun 30, 2024 | -1,960.00 |
| Mar 31, 2024 | -479.00 |
| Dec 31, 2023 | -121.00 |
| Sep 30, 2023 | 931.00 |
| Jun 30, 2023 | 1,636.00 |
| Mar 31, 2023 | -995.00 |
| Dec 31, 2022 | 1,196.00 |
| Sep 30, 2022 | -178.00 |
| Jun 30, 2022 | 488.00 |
| Mar 31, 2022 | -212.00 |
| Dec 31, 2021 | -653.00 |
| Sep 30, 2021 | 231.00 |